R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Journal ArticleDOI
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage
Janka Kisucka,Catherine Butterfield,Dan G. Duda,Sarah C. Eichenberger,Simin Saffaripour,Jerry Ware,Zaverio M. Ruggeri,Rakesh K. Jain,Judah Folkman,Denisa D. Wagner +9 more
TL;DR: The results suggest that the presence of platelets not only stimulates angiogenic vessel growth but also plays a critical role in preventing hemorrhage from theAngiogenic vessels of Matrigel.
Journal Article
Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy
G R Martin,Rakesh K. Jain +1 more
TL;DR: This work optically measured interstitial pH gradients with high resolution in normal and tumor (VX2 carcinoma) tissue in vivo by combining a fluorescence ratio imaging microscopy technique and the rabbit ear chamber preparation to permit noninvasive evaluation of new pH-modifying agents and offer unique mechanistic information about tumor pathophysiology.
Journal Article
Differential response of normal and tumor microcirculation to hyperthermia.
Thomas E. Dudar,Rakesh K. Jain +1 more
TL;DR: Differential flow response in individual microvessels was used to develop a theoretical framework relating various mechanisms of blood flow modifications due to hyperthermia, which appeared to be bimodal functions of temperature.
Journal ArticleDOI
Hindered diffusion in agarose gels: test of effective medium model
TL;DR: Values of D/D infinity calculated from this effective medium theory, without use of adjustable parameters, were in much better agreement with the measured values than were predictions based on other approaches.
Journal ArticleDOI
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Janet E. Murphy,Jennifer Y. Wo,David P. Ryan,Jeffrey W. Clark,Wenqing Jiang,Beow Y. Yeap,Lorraine C. Drapek,Leilana Ly,Christian V. Baglini,Lawrence S. Blaszkowsky,Cristina R. Ferrone,Aparna Raj Parikh,Colin D. Weekes,Ryan D. Nipp,Eunice L. Kwak,Jill N. Allen,Ryan B. Corcoran,David T. Ting,Jason E. Faris,Andrew X. Zhu,Lipika Goyal,David H. Berger,Motaz Qadan,Keith D. Lillemoe,Nilesh Talele,Rakesh K. Jain,Thomas F. DeLaney,Dan G. Duda,Yves Boucher,Carlos Fernandez-del Castillo,Theodore S. Hong +30 more
TL;DR: Total neoadjuvant therapy with FOLFIRINOX, losartan, and chemoradiotherapy provides downstaging of locally advanced pancreatic ductal adenocarcinoma and is associated with an R0 resection rate of 61%.